The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for ...

Clinical evidence and growing client demand are driving EMDR's rise as a preferred trauma therapy for adults tired of ...

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

Prolonged exposure therapy for PTSD involves reintroducing triggers while in a safe space, with a therapist to coach you through the experience. Every year, tens of millions of children, adolescents, ...

The National Institute for Health and Care Excellence (NICE) has recommended obecabtagene autoleucel (obe-cel) for adults aged 26 and older with relapsed or refractory B-cell precursor acute ...

The most comprehensive review to date of ADHD treatments has found that medication for children and adults, and cognitive behavioral therapy for adults, remain the most effective approaches, backed by ...

Becca Stanek is an experienced writer and editor who is passionate about exploring the ways we can feel better mentally and physically to get the most out of our lives. She has worked for publications ...

Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline Clinical Insights ASCO Standards are evidence-based standards to provide frameworks for best practices in cancer ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar depression. Clinical trials showed significant symptom improvement and potential ...